{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:47:24Z","timestamp":1794066444687,"version":"4.8.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bresmed Health Solutions Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The burden and treatment landscape of RA is poorly understood. This research aimed to identify evidence on quality of life, caregiver burden, economic burden, treatment patterns and clinical outcomes for patients with moderate RA in the United Kingdom.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic literature review was performed across multiple databases and screened against pre-defined inclusion criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2610 records were screened; seven studies presenting evidence for moderate RA were included. These patients were found to incur substantial burden, with moderate to severe levels of disability. Compared with patients in remission, moderate RA patients reported higher levels of disability and decreased EQ-5D utility scores. The majority of patients did not feel that their current therapy adequately controlled their disease or provided sufficient symptom relief. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) have not approved advanced therapies (such as biological disease-modifying anti-rheumatic drugs) for patients with moderate disease, which restricts access for these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The evidence available on the burden of moderate RA is limited. Despite current treatments, moderate RA still has a substantial negative impact, given that a DAS28 disease activity score defined as being in the moderate range does not qualify them for access to advanced therapies in the United Kingdom. For these patients, there is a particular need for further studies that investigate their burden and the impact of treating them earlier. Such information would help guide future treatment decisions and ensure the most effective use of resources to gain the best outcomes for patients with moderate RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab464","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T12:02:46Z","timestamp":1622635366000},"page":"4972-4981","source":"Crossref","is-referenced-by-count":13,"title":["Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Woods","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions Ltd, Sheffield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rycroft","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions Ltd, Sheffield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie Ltd, Maidenhead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophee","family":"Blanthorn-Hazell","sequence":"additional","affiliation":[{"name":"AbbVie Ltd, Maidenhead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Kent","sequence":"additional","affiliation":[{"name":"AbbVie Ltd, Maidenhead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-5222","authenticated-orcid":false,"given":"Marwan","family":"Bukhari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"2021110402580753300_keab464-B1","volume-title":"Autoimmunity: from bench to bedside","author":"Amaya-Amaya","year":"2013"},{"key":"2021110402580753300_keab464-B2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/B978-012288145-9\/50062-0","volume-title":"Women and health","author":"Dugowson","year":"2000"},{"key":"2021110402580753300_keab464-B3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/rheumatology\/key013","article-title":"Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink","volume":"57","author":"Abhishek","year":"2018","journal-title":"Rheumatology"},{"key":"2021110402580753300_keab464-B4","volume-title":"Scientific basis of healthcare: arthritis","author":"Martin","year":"2012"},{"key":"2021110402580753300_keab464-B5","year":"2018"},{"key":"2021110402580753300_keab464-B6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021110402580753300_keab464-B7","year":"2011"},{"key":"2021110402580753300_keab464-B8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"key":"2021110402580753300_keab464-B9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021110402580753300_keab464-B10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402580753300_keab464-B11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"Bergstra","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021110402580753300_keab464-B12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jval.2015.05.005","article-title":"Impact of etanercept therapy on disease activity and health-related quality of life in moderate rheumatoid arthritis patients population from a National British Observational Cohort","volume":"18","author":"Kotak","year":"2015","journal-title":"Value Health"},{"key":"2021110402580753300_keab464-B13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/13548506.2015.1111394","article-title":"Patients' and carers' views and expectations about intensive management for moderate rheumatoid arthritis: a qualitative study","volume":"21","author":"Prothero","year":"2016","journal-title":"Psychol Health Med"},{"key":"2021110402580753300_keab464-B14","doi-asserted-by":"crossref","first-page":"iii131","DOI":"10.1093\/rheumatology\/key075.437","article-title":"Factors associated with disability in rheumatoid arthritis patients with persistent moderate disease activity","volume":"57","author":"Scott","year":"2018","journal-title":"Rheumatology"},{"key":"2021110402580753300_keab464-B15","first-page":"3363","article-title":"Intensive treatment for rheumatoid arthritis reduces disease activity over time","volume":"68","author":"Gullick","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021110402580753300_keab464-B16","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-016-0897-y","article-title":"Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies","volume":"17","author":"Mian","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2021110402580753300_keab464-B17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1136\/annrheumdis-2015-208669","article-title":"Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds","volume":"75","author":"Nikiphorou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021110402580753300_keab464-B18","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00296-015-3312-3","article-title":"A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization","volume":"35","author":"Emery","year":"2015","journal-title":"Rheumatol Int"},{"key":"2021110402580753300_keab464-B19","first-page":"i97","article-title":"Baseline patient characteristics and treatment from an audit of treat to target recommendations for rheumatoid arthritis - interim results","volume":"54","author":"Buch","year":"2015","journal-title":"Rheumatology"},{"key":"2021110402580753300_keab464-B20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1185\/03007995.2012.731388","article-title":"Variation in the use of biologics in the management of rheumatoid arthritis across the UK","volume":"28","author":"Choy","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2021110402580753300_keab464-B21","doi-asserted-by":"crossref","first-page":"kex062.214","DOI":"10.1093\/rheumatology\/kex062.214","article-title":"The impact of treating to target in patients with rheumatoid arthritis: real world evidence from a single centre","volume":"56","author":"Yousif","year":"2017","journal-title":"Rheumatology"},{"key":"2021110402580753300_keab464-B22","first-page":"786","article-title":"SAT0049 21st century state of rheumatoid arthritis management in the UK","volume":"76","author":"Tan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402580753300_keab464-B23","doi-asserted-by":"crossref","first-page":"e0215999","DOI":"10.1371\/journal.pone.0215999","article-title":"Not all moderate disease is the same - identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity","volume":"14","author":"Pan","year":"2019","journal-title":"PLoS One"},{"key":"2021110402580753300_keab464-B24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3899\/jrheum.160941","article-title":"The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate","volume":"44","author":"Stevenson","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab464\/39511900\/keab464.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/4972\/41073331\/keab464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/4972\/41073331\/keab464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T03:01:26Z","timestamp":1635994886000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/4972\/6291642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6,3]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab464","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,6,3]]}}}